Fundraising FoxBrandon Capital — 2024 Investments
3 investments dated 2024 · listed companies and verified rows first · show all
Aravax is a clinical-stage biotechnology company developing next-generation immunotherapies to treat food allergies.
BiotechHealthtechMedical DevicesMelbourne, AU
Sara Prickett(Co-founder)in
Co-investorsNovartis Venture FundTenmileUniSeed Pty Ltd.
Myricx Bio is a biotech company developing antibody drug conjugates (ADCs) based on N-myristoyltransferases (NMT) inhibitors for cancer treatment.
BiotechMedical DevicesLondon, GB
Co-investorsBrandon Capital PartnersNovo HoldingsSofinnova PartnersAbingworth
Pathios Therapeutics is a drug discovery and development company working on small-molecule drugs that block the immune cell receptor GPR65, which senses the acidic tumor microenvironment, with a lead asset (PTT-4256) aimed at treating solid cancers.
BiotechHealthtechMedical DevicesOxford, GB
Alan Naylor(Founder)inStuart Hughes(Chief Scientific Officer)in
Co-investorsCanaan Partners
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.